Abstract: The present invention is a method and compound for treating specific cancerous cell lines. The invention treats liver cancer by directing a cancer-fighting drug into the liver hepatoportal circuit. The cancer-fighting drug is attached to a naturally produced molecule which functions primarily in the hepatoportal circuit and has organotropism for the hepatoportal circuit.

Abstract: The present invention is a method and compound for treating specific cancerous cell lines. The invention treats liver cancer by directing a cancer-fighting drug into the liver hepatoportal circuit. The cancer-fighting drug is attached to a naturally produced molecule which functions primarily in the hepatoportal circuit and has organotropism for the hepatoportal circuit.

Abstract: The present invention is a method and compound for treating specific cancerous cell lines. The invention treats liver cancer by directing a cancer-fighting drug into the liver hepatoportal circuit. The cancer-fighting drug is attached to a naturally produced molecule which functions primarily in the hepatoportal circuit and has organotropism for the hepatoportal circuit.

Abstract: The present invention is a method and compound for treating specific cancerous cell lines. The invention treats liver cancer by directing a cancer-fighting drug into the liver hepatoportal circuit. The cancer-fighting drug is attached to a naturally produced molecule which functions primarily in the hepatoportal circuit and has organotropism for the hepatoportal circuit.

Abstract: The present invention is a method and compound for treating liver cancer. The invention treats liver cancer by directing a cancer-fighting drug into the liver hepatoportal circuit. The cancer-fighting drug is attached to a natural produced molecule which functions primarily in the hepatoportal circuit and has organotropism for the hepatoportal circuit.

Abstract: The present invention is a method and compound for treating liver cancer. The invention treats liver cancer by directing a cancer-fighting drug into the liver hepatoportal circuit. The cancer-fighting drug is attached to a natural produced molecule which functions primarily in the hepatoportal circuit and has organotropism for the hepatoportal circuit.

Abstract: The present invention provides pyrrolo[2,1-c][1,4]benzodiazepine-glycoside prodrug of general formula 1a-b, useful as selective anticancer agents. The present invention also provides a process for the preparation of pyrrolo[2,1-c][1,4]benzodiazepine-glycoside prodrugs of general formula 1a-b. This invention also provides activation of these prodrugs by E.coli ? galactosidase and envisaged that these molecules are toxic to human cancer cell lines in the presence of the enzyme E.coli ?-galactosidase. The prodrugs 1a and 1b were also found to be toxic to human cancer HepG2 cells even in the absence of the E.coli ?-galactosidase. The toxic effect of the molecules when activated was similar to that of the parent molecules 6a and 6b, respectively.

Abstract: The present invention provides novel pyrrolo[2,1-c][1,4]benzodiazepine-glycoside prodrug of general formula 1a-b, useful as selective anticancer agents. The present invention also provides a process for the preparation of novel pyrrolo[2,1-c][1,4]benzodiazepine-glycoside prodrugs of general formula 1a-b. This invention also provides activation of these produgs by E. coli ? galactosidase and envisaged that these molecules are toxic to human cancer cell lines in the presence of the enzyme E. coli ?-galactosidase. The prodrugs 1a and 1b were also found to be toxic to human cancer HepG2 cells even in the absence of the E. coli ?-galactosidase. The toxic effect of the molecules when activated was similar to that of the parent molecules 6a and 6b, respectively.